COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Ruvanthi Kularatne

Ruvanthi Kularatne, PhDRuvanthi Kularatne, PhD
Scientist II, Pharmacology & Toxicology

Dr. Kularatne joined the Pharmacology & Toxicology division of NCL as a formulation scientist in March 2021. Her research efforts at NCL are primarily focused on developing various drug formulations. She has worked with polymeric micelles and nanoparticle formulations in the past for cancer research and has also developed depot formulations to treat the dry version of age-related macular degeneration (AMD).

Dr. Kularatne obtained her BS in Chemistry from the University of Peradeniya, Sri Lanka (2013), and PhD in Chemistry from the University of Texas at Dallas (2018). She then joined the Retina Foundation of the Southwest as a postdoctoral fellow where she co-developed multiple drug candidates to treat the dry version of AMD and oversaw in-vitro efficacy studies for the lead drug candidate. Prior to joining the NCL, Dr. Kularatne held a staff scientist position at the Retina Foundation of the Southwest where she led efforts to develop polymeric episcleral implants to deliver therapeutic agents into the retina.